Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure

This publication has 28 references indexed in Scilit:

• Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure
  Journal of the American College of Cardiology, 2002
• A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
  New England Journal of Medicine, 2001
• Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure
  Circulation, 1999
• High- versus low-dose ACE inhibition in chronic heart failure: A double-blind, placebo-controlled study of imidapril
  Journal of the American College of Cardiology, 1998
• The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure
  Journal of the American College of Cardiology, 1996
• The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
  New England Journal of Medicine, 1996
• A Prospective Evaluation of an Angiotensin-Converting–Enzyme Gene Polymorphism and the Risk of Ischemic Heart Disease
  New England Journal of Medicine, 1995
• ACE Inhibitors — A Cornerstone of the Treatment of Heart Failure
  New England Journal of Medicine, 1991
• An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.
  Journal of Clinical Investigation, 1990
• A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES
  Biometrika, 1954